Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients

Marković, Slobodan; Gadžijev, Eldar; Štabuc, Borut; Crocè, Lory Saveria; Masutti, Flora; Šurlan, Miloš; Berden, Pavel; Brenčič, Erika; Višnar-Perovič, Alenka; Sasso, Franco; Ferlan-Marolt, Vera; Mucelli, Fabio Pozzi; Cesar, Rok; Sponza, Massimo; Tiribelli, Claudio

doi:10.1016/s0168-8278(98)80162-1

Cited by 43 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 16% were in Okuda stage 1 and almost all patients were either TNM stage 3 or 4. This is more advanced than in reports from other Western countries showing 52%28 and 57%29 in Okuda stage 1 or 18% in stage 1 or 2 according to TNM classification 3031 The indolent nature of the disease in the early stages, lack of an institutionalised screening programme for HCC in liver cirrhosis, and a low index of suspicion in a region of low prevalence of HCC in the general population may explain these differences.…”

Section: Discussionmentioning

confidence: 75%

See 1 more Smart Citation

Hepatocellular carcinoma in Central Europe: prognostic features and survival

Schöniger–Hekele

Müller²,

Kutilek³

et al. 2001

Gut

213

163

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 75%

“…32-37 In patients with liver cirrhosis, Child-Pugh stage has a predominant influence on survival time 28. The importance of liver function is also underscored by our multivariate analysis in which two (bilirubin and PT) of the three most powerful independent prognostic factors were parameters of liver function.…”

Section: Discussionmentioning

confidence: 83%

Hepatocellular carcinoma in Central Europe: prognostic features and survival

Schöniger–Hekele

Müller²,

Kutilek³

et al. 2001

Gut

213

163

View full text Add to dashboard Cite

show abstract

“…Here, we outline diVerent opinions about each staging system and compare them with our results. The Okuda classiWcation (Okuda et al 1985) had been reported to be discriminatory for patients with monofocal HCC who underwent surgery in Western countries (Markovic et al 1998). The CUPI classiWcation (Leung et al 2002) was constructed from the retrospective data of 926 HCC patients consisting of mainly HBV-associated chronic liver disease in Hong Kong.…”

Section: Discussionmentioning

confidence: 99%

A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort

Yang

Zou

Lü

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…It is particularly difficult to treat HCC with tumor thrombus in the portal trunk and major branches successfully with surgery alone. 28,29 Even if aggressive surgery, such as hepatectomy and liver transplantation, is performed, satisfactory longterm survival is not expected. 30 Although Kumada et al reported that hepatic resection was feasible as an emergency option for the avoidance of lethal impendence in patients with progressive portal occlusion, the median follow-up of 10 months was relatively short, and 15% of their patients died of portal thrombosis or liver failure within 1 month after surgery.…”

Section: Discussionmentioning

confidence: 99%

Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus

Hata

Tokuuye

Sugahara

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDTreatment modalities for patients with hepatocellular carcinoma (HCC) who have portal vein tumor thrombus (PVTT) are limited and controversial; furthermore, the prognosis for these patients is extremely poor. The authors conducted a retrospective review to determine the role of proton beam therapy in the treatment of patients who had HCC with PVTT.METHODSTwelve patients with HCC who had tumor thrombus in the main trunk or major branches of the portal vein (clinical T3–T4N0M0) were treated with proton beam therapy. At the time they received proton beam irradiation, patients ranged in age from 42 years to 80 years (median, 62 years), and their tumors ranged in size from 40 mm to 110 mm (median, 60 mm) in greatest dimension. A total dose of 50–72 gray (Gy) (median, 55 Gy) in 10–22 fractions was delivered to the tumors, including PVTT.RESULTSAll tumors that were treated with proton beam therapy remained controlled at a median follow‐up of 2.3 years (range, 0.3–7.3 years). Among 12 patients, 10 patients had new liver tumors outside the irradiated volume 0.1–2.4 years after proton beam therapy, and 3 patients also had distant metastases; consequently, 8 patients died of disease, and 2 patients were salvaged by further therapies. The remaining two patients were alive with no evidence of disease 4.3 years and 6.4 years after proton beam therapy. The progression‐free survival rates were 67% at 2 years and 24% at 5 years. The median progression‐free survival was 2.3 years. According to the Acute Radiation Morbidity Scoring Criteria (Radiation Therapy Oncology Group), therapy‐related toxicity ≥ Grade 3 was not observed.CONCLUSIONSProton beam therapy for patients with HCC who had PVTT was feasible and effective. It appeared to improve survival and local control significantly for these patients. Cancer 2005. © 2005 American Cancer Society.

show abstract

Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients

Cited by 43 publications

References 31 publications

Hepatocellular carcinoma in Central Europe: prognostic features and survival

Hepatocellular carcinoma in Central Europe: prognostic features and survival

A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort

Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus

Contact Info

Product

Resources

About